The discovery of mutational events in cancer are crucial to the development of efficacious targeted therapies. Here, Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, passionately discusses the genomic advances in Waldenströms macroglobulinemia (WM), owing to the discovery of the MYD88 and CXCR4 mutations. Dr Treon highlights how these mutations have enabled better understanding of the different forms and metastatic progression of WM, aiding the development of targeted therapies that are revolutionizing the meaning of progression-free survival. This interview was recorded at the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy.
WGS: advancing Waldenström’s diagnosis, prognosis & treatment
